Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 10, 2010, Pages 884-890

  Farnik, Harald ^a   Lange, Christian M ^a   Sarrazin, Christoph ^a   Kronenberger, Bernd ^a   Zeuzem, Stefan ^a   Herrmann, Eva ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antiviral Therapy; EOT; Individualized Treatment; Treatment Duration

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL; DRUG SAFETY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; RELAPSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77957128536     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.06.019     Document Type: Article

References (32)

1. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
2. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
3. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
4. Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40:993-999.
5. Zeuzem S., Berg T., Moeller B., et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009, 16:75-90.
6. Berg T., von Wagner M., Nasser S., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-1097.
7. Pearlman B.L., Ehleben C., Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46:1688-1694.
8. Nagaki M., Shimizu M., Sugihara J.I., et al. Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders. Aliment Pharmacol Ther 2009, 30:343-351.
9. Zeuzem S., Pawlotsky J.M., Lukasiewicz E., et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005, 43:250-257.
10. Arase Y., Ikeda K., Tsubota A., et al. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 2003, 38:158-163.
11. Brouwer J.T., Nevens F., Bekkering F.C., et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004, 40:689-695.
12. Buti M., Valdes A., Sanchez-Avila F., et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003, 37:1226-1227.
13. Fuster D., Planas R., Gonzalez J., et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther 2006, 11:473-482.
14. Jensen D.M., Marcellin P., Freilich B., et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009, 150:528-540.
15. Poynard T., Bedossa P., Chevallier M., et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995, 332:1457-1462.
16. Reichard O., Foberg U., Fryden A., et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994, 19:280-285.
17. Yu M.L., Dai C.Y., Chen S.C., et al. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res 2004, 63:25-32.
18. Ikeda H., Suzuki M., Okuse C., et al. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res 2009, 39:753-759.
19. McHutchison J.G., Patel K., Schiff E.R., et al. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. Aliment Pharmacol Ther 2008, 27:422-432.
20. Kaiser P.S., Hass H., Bissinger L., et al. Extended treatment of 72 vs 48 weeks for chronic hepatitis C patients with genotype 1 and high viral load using daily consnsus interferon and ribavirin. Hepatology 2006, 44(Suppl.1):608A.
21. Ide T., Hino T., Ogata K., et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009, 104:70-75.
22. Mangia A., Minerva N., Bacca D., et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43-50.
23. Sanchez-Tapias J.M., Diago M., Escartin P., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451-460.
24. Ferenci P., Laferl P., Scherzer T.M., et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C type 1 and 4 patients with slow virological response. Gastroenterology 2010, 138:503-512.
25. Buti M., Lurie Y., Zakharova N.G., et al. Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study. J Hepatol 2009 April, 50(Suppl1):58.
26. Jacobson I.M., Brown R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46:971-981.
27. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
28. Reddy K.R., Shiffman M.L., Morgan T.R., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-129.
29. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:237-244.
30. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
31. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
32. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.